ALK and non-small cell lung carcinoma: NGS of cfDNA is useful not only for the detection of ALK fusions and resistance mutations, but also for assessing prognosis and monitoring the dynamic changes of genomic alterations in ALK+ NSCLC treated with ALK‐TKI.